Which of your patients may be appropriate for
ARIKAYCE + background regimen?

Follow 3 patient journeys to ARIKAYCE treatment

Diane patient icon

Diane, 67 years old

Click to see Diane's journey to ARIKAYCE treatment

Icon button with downward arrow

Initial patient visit

Clinical presentation (>6 months)

  • Chronic cough
  • Sputum production
  • Fatigue

Medical history

  • Bronchiectasis
  • Hyperlipidemia
  • Osteoporosis
  • Sinusitis
  • Hemoptysis
  • Weight loss

Diagnostic results

Image of lung scan Icon Open
Imaging

Microbiologic results

  • 2 AFB stains and 2 cultures positive for MAC
  • Macrolide susceptible: MIC 2.5 µg/mL
  • Amikacin (IV) susceptible

Diagnosis is MAC lung disease based on

  • Symptomatic presentation
  • CT scan showing nodular bronchiectatic disease
  • Sputum cultures positive for MAC

Click to see Diane’s journey to ARIKAYCE treatment

Icon bracket pointing down Icon bracket pointing down
  • Initiated airway clearance and active monitoring
  • Month 1
  • Month 2
  • Close monitoring

    If treatment is not initiated, patients should be closely monitored to identify any clinical and/or radiographic progression.1

  • Began multidrug regimen according to ATS/IDSA Statement
  • Month 4
  • Month 5
  • Month 6
  • Month 7
  • Month 8
  • May need more

    Although some patients can achieve culture conversion on ATS/IDSA Statement-recommended therapy, 20% to 40% experience treatment failure.2

  • Added ARIKAYCE
  • Month 10
  • Month 11
  • Treatment duration

    The ATS/IDSA Statement recommends treating patients until culture-negative on therapy for 12 months.3

Do you have a MAC patient like Diane?

Prescribing ARIKAYCE enrollment form icon
Prescribe ARIKAYCE
Right arrow icon
Mark patient icon

Eric, 59 years old

Click to see Eric’s journey to ARIKAYCE treatment

Icon button with downward arrow

Initial patient visit

Clinical presentation (>2 years)

  • Chronic cough
  • Excessive sputum production
  • Dyspnea
  • Fatigue
  • Hemoptysis
  • Emphysema

Medical history

  • COPD
  • Bronchiectasis
  • Cardiovascular disease

Diagnostic results

Image of lung scan Icon Open
Imaging

Microbiologic results

  • 1 AFB stain and 2 cultures positive for MAC
  • Macrolide susceptible: MIC 3 µg/mL
  • Amikacin (IV) susceptible: MIC 16 µg/mL*

Diagnosis is MAC lung disease based on

  • Symptomatic presentation
  • CT scan showing nodular bronchiectatic disease
  • Sputum cultures positive for MAC

Click to see Eric’s journey to ARIKAYCE treatment

Icon bracket pointing down Icon bracket pointing down
  • Initiated ATS/IDSA multidrug regimen + airway clearance
  • Month 1
  • Month 2
  • Ongoing monitoring

    The ATS/IDSA Statement recommends carefully monitoring toxicity and assessing sputum cultures monthly during therapy.3

  • Month 3
  • Month 4
  • Month 5
  • Month 7
  • Month 8
  • Month 9
  • Month 10
  • Month 11
  • May need more

    Although some patients can achieve culture conversion on ATS/IDSA Statement-recommended therapy, 20% to 40% experience treatment failure.2

  • Added ARIKAYCE
  • Month 13
  • Month 14
  • Month 15
  • Treatment duration

    The ATS/IDSA Statement recommends treating patients until culture-negative on therapy for 12 months.3

Learn more about the

Clinical data of ARIKAYCE
Right arrow icon
Jan patient icon

Jan, 74 years old

Click to see Jan's journey to ARIKAYCE treatment

Icon button with downward arrow

Initial patient visit

Clinical presentation (1 year)

  • Fatigue
  • Weight loss

Medical history

  • Asthma
  • Osteopenia
  • GERD

Diagnostic results

Image of lung scan Icon Open
Imaging

Microbiologic results

  • 2 induced sputum cultures positive for MAC
  • Macrolide susceptible: MIC 2 µg/mL
  • Amikacin (IV) susceptible

Diagnosis is MAC lung disease based on

  • Symptomatic presentation
  • CT scan showing nodular bronchiectatic disease
  • Induced sputum cultures positive for MAC

Click to see Jan’s journey to ARIKAYCE treatment

Icon bracket pointing down Icon bracket pointing down
  • Initiated airway clearance and active monitoring
  • Personalized care

    Literature suggests personalizing clearance techniques for each patient, depending on the comprehensive care needed and taking into account other lung comorbidities and disease severity.4

  • Month 1
  • Began multidrug regimen according to ATS/IDSA Statement
  • Month 3
  • Month 4
  • Month 5
  • Month 6
  • Month 7
  • Month 8
  • Month 9
  • May need more

    Although some patients can achieve culture conversion on ATS/IDSA Statement-recommended therapy, 20% to 40% experience treatment failure.2

  • Added ARIKAYCE
  • Month 11
  • Month 12
  • Month 13
  • Month 14

Learn more about the

Phase 3 trial
Right arrow icon
Footnote

*Patients enrolled in CONVERT had an IV amikacin MIC ≤64 μg/mL.5,6 The CONVERT trial is referred to as "Trial 1" in the ARIKAYCE full Prescribing Information.

AFB=acid-fast bacilli; ATS=American Thoracic Society; CT=computed tomography; GERD=gastroesophageal reflux disease; IDSA=Infectious Diseases Society of America; IV=intravenous; MAC=Mycobacterium avium complex; MIC=minimum inhibitory concentration.

References

  1. Daley CL. Mycobacterium avium complex disease. Microbiol Spectr. 2017;5(2):TNMI7-0045-2017. doi:10.1128/microbiolspec.TNMI7-0045-2017.
  2. Koh W-J, Hong G, Kim S-Y, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57(5):2281-2285.
  3. Griffith DE, Aksamit T, Brown-Elliott BA, et al; for the ATS Mycobacterial Diseases Subcommittee. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416.
  4. McIlwaine M, Bradley J, Elborn JS, Moran F. Personalising airway clearance in chronic lung disease. Eur Respir Rev. 2017;26(143):160086. doi:10.1183/16000617.0086-2016.
  5. ARIKAYCE [package insert]. Bridgewater, NJ: Insmed Incorporated; 2018.
  6. Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559-1569.